Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S, Committee I. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. Journal Of Thoracic Oncology 2022, 17: 1335-1354. PMID: 36184066, DOI: 10.1016/j.jtho.2022.09.109.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsTumor mutational burdenLung Cancer Pathology CommitteePD-L1 immunohistochemistryPredictive biomarkersImmunotherapy biomarkersLung cancerPathology CommitteeBackbone of treatmentSubset of patientsMost lung cancersEarly-stage tumorsCompanion diagnostic assayAdjuvant settingNeoadjuvant immunotherapyCheckpoint inhibitorsMetastatic diseasePathologic responseImmune microenvironmentStage tumorsMutational burdenImmunotherapyPrognosis predictionImmunohistochemistryBiomarkers